Page 61 - NobleCon19revC2_Neat

Cocrystal Pharma, Inc.

SELECTED FINANCIAL ITEMS COCP

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit (3.29) (3.91) (2.80) (4.19) (14.19)
Gross Margin NM NM NM NM NM
EBIT (4.50) (5.11) (4.34) (6.04) (20.00)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (4.50) (5.19) (4.17) (4.17) (18.02)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 40.84 37.84 36.28 32.61 32.61
Cash & Short Term Investments 37.14 33.98 32.42 29.74 29.74
% of Assets 91% 90% 89% 91% 91%
Current Assets -Total 40.18 37.24 35.76 32.21 32.21
% of Assets 98% 98% 99% 99% 99%
Total Liabilities 1.27 3.17 1.60 1.92 1.92
% of Assets 3% 8% 4% 6% 6%
Current Liabilities - Total 1.22 3.15 1.59 1.92 1.92
% of Assets 3% 8% 4% 6% 6%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 39.57 34.67 34.68 30.69 30.69
% of Assets 97% 92% 96% 94% 94%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (4.89) (3.11) (5.55) (2.68) (16.23)
Net Cash Flow - Investing (0.01) (0.05) (0.01) 0.00 (0.07)
Net Cash Flow - Financing (0.01) (0.01) 4.00 0.00 3.99

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference